Celcuity Inc. Common Stock (CELC) Stock Price

CELCStock

$56.58+7.71%52W

Market Cap$2.77B

P/E—

PEG Ratio—

Div yield—

Beta0.13

CELC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-63.09%

Price vs S&P 500 (4W)-31.32%

VGM Score27.53

CELC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$1.08	-$1.07	+0.93%(+$0.01)
Q1 2026	May 14, 2026	-$0.89	-$0.86	+3.37%(+$0.03)
Q4 2025	Mar 25, 2026	-$1.01	-$0.73	+27.72%(+$0.28)
Q3 2025	Nov 12, 2025	-$0.96	-$0.78	+18.47%(+$0.18)
Q2 2025	Aug 14, 2025	-$0.84	-$0.93	-10.06%(-$0.09)

CELC Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.33

Industry Peers — Health Services(30)

Symbol	Value Score	Growth Score	Momentum Score	P/E Ratio (Annual)	Revenue Growth TTM (YoY)	Operating Margin (TTM)	ROE (TTM)	Price
CELCCelcuity Inc. Common Stock	—	—	D	—	—	—	-244.6%	$56.58
NTRANatera, Inc. Common Stock	F	A	A	—	37.8%	-10.7%	-11.7%	$393.44
DGXQuest Diagnostics Inc.	C	D	B	26.1x	9.9%	14.1%	14.5%	$235.00
LHLabcorp Holdings Inc.	C	D	B	29.4x	6.4%	10.4%	11.6%	$317.95
GHGuardant Health, Inc. Common Stock	F	A	B	—	42.7%	-40.2%	-246.6%	$158.60
CAICaris Life Sciences, Inc. Common Stock	F	A	B	—	38.5%	12.7%	18.8%	$30.56
RDNTRadNet, Inc. Common Stock	D	C	C	1779.3x	18.9%	3.0%	-1.9%	$68.80
GRALGRAIL, Inc. Common Stock	D	B	B	—	23.1%	-338.4%	-15.9%	$117.81
BLLNBillionToOne, Inc. Class A Common Stock	F	F	C	621.1x	—	10.9%	8.9%	$98.12
VCYTVeracyte, Inc.	D	B	C	52.2x	17.3%	19.6%	8.6%	$43.12
CDNACareDx, Inc.	D	B	A	18.3x	34.4%	23.6%	32.8%	$64.00
FTREFortrea Holdings Inc. Common Stock	C	F	A	—	-2.1%	-0.4%	-15.5%	$22.49
PSNLPersonalis, Inc. Common Stock	F	D	B	—	-13.3%	-164.1%	-46.5%	$15.65
FRNMFreenome, Inc. Common stock	—	F	F	1507.5x	—	—	-0.9%	$11.75
LMRILumexa Imaging Holdings, Inc. Common Stock	C	C	C	—	—	8.2%	-8.7%	$10.78
CSTLCastle Biosciences, Inc. Common Stock	D	B	B	47.3x	3.2%	-9.0%	-4.2%	$31.96
FLGTFulgent Genetics, Inc. Common Stock	C	D	C	—	6.8%	-37.8%	-7.9%	$19.81
YDESYD Bio Limited Ordinary Shares	—	—	C	—	—	—	149.8%	$5.92
BDSXBiodesix, Inc. Common Stock	D	B	B	—	34.5%	-20.0%	-164.9%	$23.66
XGNExagen Inc. Common Stock	D	C	B	—	20.8%	-18.6%	-121.6%	$7.72
BNRBurning Rock Biotech Limited American Depositary Shares	C	F	B	—	-6.7%	-13.0%	-13.0%	$12.90
PCSCPerceptive Capital Solutions Corp Class A Ordinary Shares	—	F	C	147.2x	—	—	0.1%	$12.19
SERASera Prognostics, Inc. Class A Common Stock	D	C	C	—	-35.2%	-53282.9%	-46.7%	$2.06
MDXHMDxHealth SA Ordinary Shares	C	D	F	—	-5.2%	-16.6%	-305.0%	$0.21
AMSAmerican Shared Hospital Services	A	C	C	4.1x	4.0%	-11.8%	-7.5%	$1.28
ADVBAdvanced Biomed Inc. Common Stock	A	—	D	—	—	—	83.9%	$3.98
ACONAclarion, Inc. Common Stock	—	B	F	—	33.1%	-11592.2%	-59.3%	$1.85
BGLCBioNexus Gene Lab Corp Common stock	B	F	F	—	-67.1%	-81.8%	-32.9%	$1.20
ACONWAclarion, Inc. Warrant	—	—	D	—	—	—	—	$0.03
EXASExact Sciences Corp	F	B	B	—	17.7%	-6.3%	-8.5%	$0.00
YDESWYD Bio Limited Warrants	—	—	B	—	—	—	—	$0.60

About Celcuity Inc. Common Stock

Celcuity is a clinical-stage oncology biotechnology company developing gedatolisib, a dual PI3K/mTOR inhibitor with a differentiated mechanism of action compared to existing therapies. The company's lead program is in Phase 3 development (VIKTORIA-1), evaluating gedatolisib combined with fulvestrant with or without palbociclib for hormone receptor-positive, HER2-negative advanced breast cancer.